.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Baxter
Fuji
QuintilesIMS
UBS
Chubb
Harvard Business School
Dow
Mallinckrodt

Generated: June 24, 2017

DrugPatentWatch Database Preview

ABSORICA Drug Profile

« Back to Dashboard

What is the patent landscape for Absorica, and what generic Absorica alternatives are available?

Absorica is a drug marketed by Ranbaxy and is included in one NDA. There are five patents protecting this drug and three Paragraph IV challenges.

This drug has ten patent family members in eight countries.

The generic ingredient in ABSORICA is isotretinoin. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.

Summary for Tradename: ABSORICA

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list37
Clinical Trials: see list1
Patent Applications: see list4,870
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ABSORICA at DailyMed

Pharmacology for Tradename: ABSORICA

Ingredient-typeRetinoids
Drug ClassRetinoid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-004May 25, 2012BXRXYesYes8,952,064► SubscribeY ► Subscribe
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-004May 25, 2012BXRXYesYes9,078,925► SubscribeY ► Subscribe
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-001May 25, 2012BXRXYesNo7,435,427► SubscribeY ► Subscribe
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-003May 25, 2012BXRXYesNo7,435,427► SubscribeY ► Subscribe
Ranbaxy
ABSORICA
isotretinoin
CAPSULE;ORAL021951-006Aug 15, 2014RXYesNo9,089,534► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ABSORICA

Drugname Dosage Strength RLD Submissiondate
isotretinoinCapsules30 mg and 40 mgAbsorica12/31/2012
isotretinoinCapsules20 mgAbsorica1/7/2013
isotretinoinCapsules20 mgAbsorica6/19/2013

International Patent Family for Tradename: ABSORICA

Country Document Number Estimated Expiration
European Patent Office1318791► Subscribe
Spain2225600► Subscribe
World Intellectual Property Organization (WIPO)0224172► Subscribe
Canada2836228► Subscribe
Canada2423170► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Baxter
McKinsey
Colorcon
Harvard Business School
UBS
Daiichi Sankyo
QuintilesIMS
Novartis
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot